| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 547 | 2020 |
| Mucormycosis in hematologic malignancies: an emerging fungal infection A Nosari, P Oreste, M Montillo, G Carrafiello, M Draisci, G Muti, A Molteni, ... Haematologica 85 (10), 1068-1071, 2000 | 271 | 2000 |
| Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 … EN Oliva, C Alati, V Santini, A Poloni, A Molteni, P Niscola, F Salvi, ... The Lancet Haematology 4 (3), e127-e136, 2017 | 180 | 2017 |
| Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT L Arcaini, S Burcheri, A Rossi, M Paulli, R Bruno, F Passamonti, ... Annals of Oncology 18 (2), 346-350, 2007 | 150 | 2007 |
| Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial F Perrone, MC Piccirillo, PA Ascierto, C Salvarani, R Parrella, AM Marata, ... Journal of translational medicine 18 (1), 405, 2020 | 147 | 2020 |
| Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS 0306 T rial) E Angelucci, V Santini, AA Di Tucci, G Quaresmini, C Finelli, A Volpe, ... European journal of haematology 92 (6), 527-536, 2014 | 106 | 2014 |
| Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination L Arcaini, S Burcheri, A Rossi, F Passamonti, M Paulli, E Boveri, ... The Oncologist 11 (3), 285-291, 2006 | 88 | 2006 |
| Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic … MG Della Porta, CH Jackson, EP Alessandrino, M Rossi, A Bacigalupo, ... Leukemia 31 (11), 2449-2457, 2017 | 66 | 2017 |
| Canakinumab as treatment for COVID-19-related pneumonia: a prospective case-control study D Generali, G Bosio, F Malberti, A Cuzzoli, S Testa, L Romanini, ... International journal of infectious diseases 104, 433-440, 2021 | 61 | 2021 |
| A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis M Maffioli, B Mora, S Ball, A Iurlo, EM Elli, MC Finazzi, N Polverelli, ... Blood advances 6 (6), 1855-1864, 2022 | 48 | 2022 |
| Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes G Falconi, E Fabiani, A Piciocchi, M Criscuolo, L Fianchi, ... Leukemia 33 (3), 785-790, 2019 | 41 | 2019 |
| Prognostic value of circulating CD34+ cells in myelodysplastic syndromes C Cesana, C Klersy, B Brando, A Nosari, B Scarpati, L Scampini, ... Leukemia research 32 (11), 1715-1723, 2008 | 34 | 2008 |
| Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes A Molteni, A Nosari, M Montillo, A Cafro, C Klersy, E Morra Haematologica 90 (8), 1145-1147, 2005 | 33 | 2005 |
| Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective … EN Oliva, V Santini, G Zini, GA Palumbo, A Poloni, A Cortelezzi, MT Voso, ... Blood 120 (21), 923, 2012 | 30 | 2012 |
| Changes of Prothrombin Fragment 1+ 2 (F 1+ 2) as a Function of Increasing Intensity of Oral Anticoagulation A Tripodi, M Cattaneo, A Molteni, BM Cesana, PM Mannucci Thrombosis and haemostasis 79 (03), 571-573, 1998 | 27 | 1998 |
| Real‐world experience with decitabine as a first‐line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy M Bocchia, A Candoni, E Borlenghi, M Defina, C Filì, C Cattaneo, ... Hematological Oncology 37 (4), 447-455, 2019 | 26 | 2019 |
| Invasive fungal infections in lymphoproliferative disorders: a monocentric retrospective experience AM Nosari, ML Pioltelli, M Riva, L Marbello, M Nichelatti, A Greco, ... Leukemia & Lymphoma 55 (8), 1844-1848, 2014 | 25 | 2014 |
| Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients M Maffioli, T Giorgino, B Mora, A Iurlo, E Elli, MC Finazzi, M Caramella, ... Blood Advances 3 (21), 3196-3200, 2019 | 24 | 2019 |
| ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective … F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... Lancet Haematol 7 (10), e737-e745, 2020 | 23 | 2020 |
| Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations C Girmenia, A Candoni, M Delia, R Latagliata, A Molteni, EN Oliva, ... Blood reviews 34, 16-25, 2019 | 23 | 2019 |
